Last reviewed · How we verify
89Zr-GSK3128349 1 mg
89Zr-GSK3128349 1 mg is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | 89Zr-GSK3128349 1 mg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Influenza
- Nasopharyngitis
- Flatulence
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 89Zr-GSK3128349 1 mg CI brief — competitive landscape report
- 89Zr-GSK3128349 1 mg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about 89Zr-GSK3128349 1 mg
What is 89Zr-GSK3128349 1 mg?
89Zr-GSK3128349 1 mg is a Small molecule drug developed by GlaxoSmithKline.
Who makes 89Zr-GSK3128349 1 mg?
89Zr-GSK3128349 1 mg is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is 89Zr-GSK3128349 1 mg in?
89Zr-GSK3128349 1 mg is in Phase 1.
What are the side effects of 89Zr-GSK3128349 1 mg?
Common side effects of 89Zr-GSK3128349 1 mg include Influenza, Nasopharyngitis, Flatulence.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: 89Zr-GSK3128349 1 mg vs similar drugs
- Pricing: 89Zr-GSK3128349 1 mg cost, discount & access